Daily Stock Analysis, AMPE, Ampio Pharmaceuticals Inc, priceseries

Ampio Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
0.43
Close
0.42
High
0.45
Low
0.42
Previous Close
0.43
Daily Price Gain
-0.01
YTD High
1.31
YTD High Date
Jun 14, 2019
YTD Low
0.26
YTD Low Date
Oct 29, 2019
YTD Price Change
-0.02
YTD Gain
-4.55%
52 Week High
1.31
52 Week High Date
Jun 14, 2019
52 Week Low
0.26
52 Week Low Date
Oct 29, 2019
52 Week Price Change
-0.21
52 Week Gain
-33.34%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 29. 2017
0.61
Oct 23. 2017
1.01
16 Trading Days
65.27%
Link
LONG
Nov 15. 2017
1.23
Nov 30. 2017
1.59
10 Trading Days
29.30%
Link
LONG
Dec 12. 2017
1.68
Jan 2. 2018
3.08
13 Trading Days
83.58%
Link
LONG
Mar 22. 2018
2.85
Apr 10. 2018
3.34
12 Trading Days
17.09%
Link
LONG
Jul 20. 2018
2.63
Aug 3. 2018
2.78
10 Trading Days
5.69%
Link
Company Information
Stock Symbol
AMPE
Exchange
NYSE MKT
Company URL
http://www.ampiopharma.com
Company Phone
720-437-6500
CEO
Michael Macaluso
Headquarters
Colorado
Business Address
373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD, CO 80112
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001411906
About

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company, that engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. The company was founded by David Bar-Or in April 2010 and is headquartered in Greenwood Village, CO.

Description

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.